Author:
Wagener Emma D.A.,Souma Nao,Hodakowski Alexander,Martinez Carlos,Fox Patrick,Mehta Rupal,O’Brien Matthew J.,Bolon Maureen,Kulik Laura,Yang Guang-Yu,Isakova Tamara,Block Geoffrey A.,Cheung Alfred K.,Flessner Michael F.,Fried Linda,Gassman Jennifer J.,Ix Joachim H.,Kusek John W.,Raj Dominic,Raphael Kalani L.,Sprague Stuart M.,Wolf Myles
Reference21 articles.
1. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease;Isakova;Kidney Int,2011
2. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis;Palmer;JAMA,2011
3. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease;Isakova;JAMA,2011
4. A randomized, double-blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients;Cheng;Clin J Am Soc Nephrol,2008
5. Oral nicotinamide reduces serum phosphorus, increases HDL, and induces thrombocytopenia in hemodialysis patients: a double-blind randomized clinical trial;Shahbazian;Nefrologia,2011